Robert H. Smith School of Business
The Motley Fool

Market Foolery Featured Podcasts

  • MarketFoolery 10.01.2014
    Motley Fool Funds analyst Bill Barker breaks down the business of DreamWorks Animation and Disney’s ability to monetize film-based products.  Plus we analyze the FCC’s decision to eliminate the “blackout rule”, the potential for a sports programming bubble, and why our fantasy football team needs a new name.
  • MarketFoolery: 09.30.2014
    On today’s show the guys discuss eBay’s breakup with PayPal, Mark Fields’ tough week at Ford, and what the future holds for GoPro.
  • MarketFoolery: 09.29.2014
    DreamWorks Animation soars on reports it’s about to be bought by SoftBank.  Starboard Value makes a public push for Yahoo to buy AOL.  We analyze those stories and dip into the Fool Mailbag.
Capital Business
Posted at 11:13 AM ET, 07/16/2012

GlaxoSmithKline buys Human Genome Sciences for $3.6B


Human Genome Sciences' headquarters in Rockville. (Jeffrey MacMillan - Capital Business)
British drugmaker GlaxoSmithKline has agreed to pay $3.6 billion for Rockville-based Human Genome Sciences after a months-long acquisition dispute over the company’s true value.

Glaxo has extended multiple buyout offers since April to both the HGS board of directors and its shareholders that valued the company at $2.6 billion, or $13 per share, but the company repeatedly rejected them as too low.

This latest agreement will fetch $14.25 per share in cash for HGS, a transaction value worth about $3.6 billion on an equity basis, or approximately $3 billion net of cash and debt, the companies said.

The deal brings an end to what had become an increasingly heated battle for control of the company.

Glaxo had attempted to bypass the board and purchase stock directly from investors. HGS then thwarted that effort with a poison pill, but gained a lawsuit from some disgruntled shareholders in response.

The two firms are development and marketing partners on several drugs, including Benlysta, which was approved by the Food and Drug Administration last year to treat systemic lupus.

By  |  11:13 AM ET, 07/16/2012

 
Read what others are saying
     

    © 2011 The Washington Post Company